Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?

Detalles Bibliográficos
Autor principal: Okada, Fumihiko
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654522/
https://www.ncbi.nlm.nih.gov/pubmed/19300550
_version_ 1782165379797221376
author Okada, Fumihiko
author_facet Okada, Fumihiko
author_sort Okada, Fumihiko
collection PubMed
description
format Text
id pubmed-2654522
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26545222009-03-19 Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal? Okada, Fumihiko Neuropsychiatr Dis Treat Letters Dove Medical Press 2007-02 /pmc/articles/PMC2654522/ /pubmed/19300550 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Letters
Okada, Fumihiko
Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
title Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
title_full Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
title_fullStr Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
title_full_unstemmed Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
title_short Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
title_sort why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
topic Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654522/
https://www.ncbi.nlm.nih.gov/pubmed/19300550
work_keys_str_mv AT okadafumihiko whydoesmilnacipranproducesofewdiscontinuationsyndromesfollowingabruptwithdrawal

Ejemplares similares